🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis (jPsA), Moderately to severely active ulcerative colitis (UC), Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  2. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  3. Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, STELARA 90 mg solution for injection in pre-filled syringe, Placebo for Ustekimumab, Placebo for Guselkumab, STELARA 130 mg concentrate for solution for infusion

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  4. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  5. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Type Psoriasis

    phase 3 small molecule active

    1 trial

  6. Guselkumab 1 mL PFS Placebo, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. Guselkumab 1 mL PFS Placebo, Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 2 mL PFS Placebo, Guselkumab 0.5 mL Varioject Placebo, Guselkumab, Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  8. Guselkumab, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab 1 mL PFS Placebo, Guselkumab 2 mL PFS Placebo

    Janssen-Cilag International N.V.

    Moderate to Severly Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  9. Guselkumab, Placebo 0.5ml equivalent, Guselkumab- Solution for infusion- 10 mg/ml, Placebo 2.0ml equivalent, Guselkumab, Placebo 1.0ml equivalent, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  10. Guselkumab- Solution for infusion- 10 mg/ml, Placebo to Guselkumab, Placebo to Guselkumab solution for injection in pre-filled syringe -100 mg/ml, Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL, Guselkumab, Placebo to Guselkumab- Solution for infusion- 10 mg/ml

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  11. Gynaecological follow-up

    GlaxoSmithKline

    Infections, Papillomavirus

    phase 3 other completed

    1 trial

  12. H. pylori vaccine

    BRIGHT MINDS BIOSCIENCES INC.

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  13. H. pylori vaccine

    Jiangsu Province Centers for Disease Control and Prevention

    H. Pylori Infection

    phase 3 mab completed

    1 trial

  14. HEC74647PA+HEC110114

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic HCV Infection

    phase 3 small molecule completed

    1 trial

  15. HLD200 methylphenidate hydrochloride capsules

    COLLEGIUM PHARMACEUTICAL, INC

    Attention Deficit Hyperactivity Disorder

    phase 3 small molecule terminated

    1 trial

  16. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  17. HYDROXYCHLOROQUINE, METHOTREXATE, Remsima 120 mg solution for injection in pre-filled pen, METHOTREXATE, IBUPROFEN, Placebo (To evaluate the efficacy and safety of CT-P13, and mainatain blindness during the study, Placebo will be administered.), PARACETAMOL, FOLIC ACID, HYDROCORTISONE

    Celltrion Healthcare Australia Pty Ltd

    Rheumatoid arthritis

    phase 3 small molecule active

    1 trial

  18. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

  19. Hemlibra 150 mg/mL solution for injection, Hemlibra 30 mg/mL solution for injection

    Hoffmann-La Roche

    Mild or moderate hemophilia A without FVIII inhibitors

    phase 3 small molecule active

    1 trial

  20. Herzuma 150 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, DS-8201a, CAPECITABINE, 5-Fluorouracil Ebewe 50 mg/ml concentrat pentru soluţie injectabilă/perfuzabilă, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CAPECITABINE, Oxaliplatin AqVida 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Daiichi Sankyo

    Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or Gastroesophageal Junction Cancer

    phase 3 small molecule active

    1 trial

  21. Human Erythropoiesis Injection (CHO cell)

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Kidney Failure, Chronic

    phase 3 small molecule active

    1 trial

  22. Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Norovirus Infections

    phase 3 mab completed

    1 trial

  23. Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)

    Takeda

    Hemophilia A

    phase 3 small molecule completed

    1 trial

  24. Human rotavirus liquid vaccine

    GlaxoSmithKline

    Infections, Rotavirus

    phase 3 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources